Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    COAST /D9108C00001
Previous Study | Return to List | Next Study

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03822351
Recruitment Status : Active, not recruiting
First Posted : January 30, 2019
Last Update Posted : November 5, 2020
Sponsor:
Information provided by (Responsible Party):
MedImmune LLC

Brief Summary:
The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.

Condition or disease Intervention/treatment Phase
Stage III Non-small Cell Lung Cancer Unresectable Drug: Durvalumab + Oleclumab Drug: Durvalumab Drug: Durvalumab + Monalizumab Phase 2

Detailed Description:
Study D9108C00001 (COAST) is a Phase 2, open-label, multicenter, randomized multidrug platform study assessing the efficacy and safety of durvalumab alone vs durvalumab in combination with novel agents in subjects with locally advanced, unresectable, Stage III non-small cell lung cancer (NSCLC).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 189 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Intervention Model Description:

At study onset subjects will be randomized equally to all study treatment arms open for enrollment and will remain on study treatment for up to 12 months.

Study treatment will be discontinued upon disease progression, unacceptable toxicity, or other reason. The treatment arms are Control Arm, Arm A and Arm B.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)
Actual Study Start Date : December 19, 2018
Estimated Primary Completion Date : July 11, 2023
Estimated Study Completion Date : July 11, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Durvalumab

Arm Intervention/treatment
Experimental: Control Arm (Durvalumab monotherapy)
durvalumab IV
Drug: Durvalumab
Durvalumab
Other Name: Durvalumab (MEDI-4736)

Experimental: Arm A (durvalumab + oleclumab):
durvalumab IV and oleclumab IV
Drug: Durvalumab + Oleclumab
Durvalumab + Oleclumab
Other Names:
  • Durvalumab (MEDI-4736)
  • Oleclumab (MEDI-9447)

Experimental: Arm B (durvalumab + monalizumab)
durvalumab IV and monalizumab IV
Drug: Durvalumab + Monalizumab
Durvalumab + Monalizumab
Other Names:
  • Durvalumab (MEDI-4736)
  • Monalizumab (IPH2201)




Primary Outcome Measures :
  1. Objective Response (OR) rate as a measure of antitumor activity of durvalumab alone vs durvalumab in combination with novel agents [ Time Frame: ORR at 16weeks after randomization is the timing for radiologic assessment of the primary endpoint ]
    Best overall response of confirmed CR or confirmed PR according to RECIST v1.1


Secondary Outcome Measures :
  1. Incidence of Adverse Events as a measure of safety during the treatment period [ Time Frame: From time of informed consent through treatment period (12 months) or up to 3 months post last dose of study treatment ]
    The secondary endpoint of safety as assessed by the presence of adverse events and serious adverse events

  2. Duration of Response (DoR) as a measure of efficacy of durvalumab alone vs durvalumab in combination with novel agents [ Time Frame: From time of first documented response until disease progression or up to a maximum of 5 years after randomization ]
    The duration from the first documentation of a subsequently confirmed OR to the first documentation of a disease progression according to RECIST v1.1 or death due to any cause, whichever occurs first. Only subjects who have achieved OR (confirmed CR or confirmed PR) will be evaluated for DoR

  3. Disease Control (DC) as a measure of efficacy of durvalumab alone vs durvalumab in combination with novel agents [ Time Frame: From time of randomization until disease progression or up to a maximum of 5 years ]
    confirmed CR, confirmed PR, or SD based on RECIST v1.1

  4. Progression-Free Survival (PFS) and Progression-Free Survival 12 month landmark rate (PFS-12) as a measure of efficacy of durvalumab alone vs durvalumab in combination with novel agents [ Time Frame: From time of randomization until disease progression or up to a maximum of 5 years ]
    From randomization until the first documentation of disease progression according to RECIST v1.1 or death due to any cause, whichever occurs first

  5. Serum durvalumab concentration levels [ Time Frame: From randomization up to 15 months after first treatment ]
    Pharmacokinetics of durvalumab

  6. Serum concentration levels of durvalumab or novel agents [ Time Frame: From randomization up to 15 months after first treatment ]
    Pharmacokinetics of durvalumab alone and/or in combination with novel agents

  7. Development of detectable anti-drug antibody (ADA) to durvalumab [ Time Frame: From randomization up to 15 months after first treatment ]
    Immunogenicity of durvalumab

  8. Development of detectable anti-drug antibody (ADA) to durvalumab or novel biologic agents [ Time Frame: From randomization up to 15 months after first treatment ]
    Immunogenicity of durvalumab alone and/or in combination with novel biologic agents

  9. Number of patients with clinically significant laboratory values as a measure of safety [ Time Frame: From screening until disease progression or death, up to a maximum of 5 years after randomization ]
    Assess the presence of clinically significant laboratory values taken at times indicated in the assessment schedule from baseline in terms of number of patients with abnormal values

  10. Incidence of clinically significant vital sign values as a measure of safety [ Time Frame: From screening until disease progression or death, up to a maximum of 5 years after randomization ]
    Assess the presence of clinically significant vital sign values from baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  1. Written informed consent and any locally required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluation
  2. Age 18 years or older
  3. Body weight ≥ 35 kg
  4. Subjects must have histologically or cytologically documented NSCLC who present with locally advanced, unresectable, Stage III disease
  5. Subjects must have completed, without progressing, definitive cCRT within 42 days prior to being randomized into the study:
  6. Provision of tumor tissue sample, when available, from original diagnosis obtained before initiation of chemoradiotherapy
  7. Life expectancy ≥ 12 weeks
  8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  9. Subjects must have at least one previously irradiated tumor lesion that can be measured by RECIST v1.1

Main Exclusion Criteria:

  1. Mixed small cell and non-small cell lung cancer histology
  2. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug.
  3. Prior exposure to any anti-PD1, anti-PD-L1, or anti-CTLA4 antibody for treatment of NSCLC
  4. Subjects with history of ≥ Grade 2 pneumonitis from prior chemoradiation therapy
  5. Subjects with a history of venous thrombosis within the past 3 months
  6. Subjects with history of myocardial infarction, transient ischemic attack, or stroke in the past 6 months
  7. Congestive heart failure
  8. Active or prior documented autoimmune or inflammatory disorders
  9. History of active primary immunodeficiency
  10. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
  11. History of allogenic organ transplantation
  12. QTcF interval ≥ 470 ms
  13. History of another primary malignancy
  14. Concurrent enrollment in another therapeutic clinical study or during the follow-up period of an interventional study. Enrollment in observational studies will be allowed
  15. Females who are pregnant, lactating, or intend to become pregnant during their participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03822351


Locations
Hide Hide 86 study locations
Layout table for location information
United States, Arizona
Research Site
Scottsdale, Arizona, United States, 85259
United States, California
Research Site
Anaheim, California, United States, 92801
Research Site
Bakersfield, California, United States, 93309
Research Site
Duarte, California, United States, 91010
Research Site
Fresno, California, United States, 93720
Research Site
Sacramento, California, United States, 95825
United States, Colorado
Research Site
Aurora, Colorado, United States, 80045
United States, Connecticut
Research Site
New Haven, Connecticut, United States, 06510
Research Site
West Haven, Connecticut, United States, 06516
United States, District of Columbia
Research Site
Washington, District of Columbia, United States, 20007
United States, Florida
Research Site
Boca Raton, Florida, United States, 33486
Research Site
Orlando, Florida, United States, 32804
Research Site
Winter Haven, Florida, United States, 33881
United States, Illinois
Research Site
Hinsdale, Illinois, United States, 60521
United States, Kansas
Research Site
Wichita, Kansas, United States, 67214
United States, Kentucky
Research Site
Lexington, Kentucky, United States, 40503
Research Site
Louisville, Kentucky, United States, 40202
United States, Louisiana
Research Site
Baton Rouge, Louisiana, United States, 70808
Research Site
Covington, Louisiana, United States, 70433
United States, Maryland
Research Site
Baltimore, Maryland, United States, 21237
Research Site
Bethesda, Maryland, United States, 20817
United States, Nebraska
Research Site
Lincoln, Nebraska, United States, 68510
United States, New York
Research Site
New York, New York, United States, 10029
Research Site
New York, New York, United States, 10065
United States, Oregon
Research Site
Portland, Oregon, United States, 97213
Research Site
Portland, Oregon, United States, 97227-1191
United States, Pennsylvania
Research Site
Gettysburg, Pennsylvania, United States, 17325
Research Site
Lancaster, Pennsylvania, United States, 17604
Research Site
Philadelphia, Pennsylvania, United States, 19104
United States, South Dakota
Research Site
Sioux Falls, South Dakota, United States, 57105
United States, Tennessee
Research Site
Memphis, Tennessee, United States, 38117
Research Site
Memphis, Tennessee, United States, 38120
United States, Texas
Research Site
Tyler, Texas, United States, 75701
United States, Utah
Research Site
Salt Lake City, Utah, United States, 84112
United States, Virginia
Research Site
Fairfax, Virginia, United States, 22031
Research Site
Fort Belvoir, Virginia, United States, 22060
Research Site
Richmond, Virginia, United States, 23230
United States, Washington
Research Site
Tacoma, Washington, United States, 98405
United States, West Virginia
Research Site
Morgantown, West Virginia, United States, 26506
Canada, Alberta
Research Site
Edmonton, Alberta, Canada, T6G 1Z2
Canada, Ontario
Research Site
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Research Site
Montreal, Quebec, Canada, H4A 3J1
France
Research Site
Bordeaux Cedex, France, 33076
Research Site
Brest, France, 29609
Research Site
Bron, France, 69677
Research Site
Creteil, France, 94010
Research Site
La Rochelle Cedex, France, 17019
Research Site
Lille, France, 59037
Research Site
Limoges Cedex, France, 87042
Research Site
Lyon Cedex 04, France, 69004
Research Site
Marseille Cedex 9, France, 13009
Research Site
Nice, France, 06189
Research Site
Pierre Benite, France, 69495
Research Site
Rennes Cedex 9, France, 35033
Research Site
Strasbourg Cedex, France, 67085
Research Site
Toulouse, France, 31059
Hong Kong
Research Site
Hong Kong, Hong Kong
Research Site
Jordan, Hong Kong
Research Site
Kowloon, Hong Kong
Italy
Research Site
Catania, Italy, 95125
Research Site
Cremona, Italy, 26100
Research Site
Milano, Italy, 20132
Research Site
Milano, Italy, 20133
Research Site
Padova, Italy, 35128
Research Site
Palermo, Italy, 90127
Research Site
Palermo, Italy, 90146
Research Site
Ravenna, Italy, 48121
Research Site
Siena, Italy, 53100
Poland
Research Site
Gdynia, Poland, 81-519
Research Site
Lodz, Poland, 90-153
Research Site
Lodz, Poland, 90-242
Portugal
Research Site
Lisboa, Portugal, 1400-038
Research Site
Lisboa, Portugal, 1500-650
Research Site
Porto, Portugal, 4099-001
Research Site
Porto, Portugal, 4200-072
Spain
Research Site
A Coruña, Spain, 15006
Research Site
Badajoz, Spain, 06008
Research Site
Barcelona, Spain, 08035
Research Site
Barcelona, Spain, 08041
Research Site
Barcelona, Spain, 08916
Research Site
Castelló de la Plana, Spain, 12002
Research Site
Madrid, Spain, 28034
Research Site
Málaga, Spain, 29010
Research Site
Valencia, Spain, 46014
Taiwan
Research Site
Chiayi, Taiwan, 61363
Research Site
Taichung, Taiwan, 402
Sponsors and Collaborators
MedImmune LLC
Layout table for additonal information
Responsible Party: MedImmune LLC
ClinicalTrials.gov Identifier: NCT03822351    
Other Study ID Numbers: D9108C00001
First Posted: January 30, 2019    Key Record Dates
Last Update Posted: November 5, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by MedImmune LLC:
Locally Advanced NSCLC
Non-small Cell Lung Cancer
Cancer
Lung
Unresectable
Stage III
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Durvalumab
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs